NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
13 5월 2024 - 9:30PM
Business Wire
Approximately 16 million Americans suffer from
dry eye disease with the U.S. market for dry eye treatment
projected to reach $4.86 billion by 2030
NovaBay® Pharmaceuticals, Inc. (NYSE American:
NBY), a company developing and commercializing high-quality eyecare
and wound care products, announces the introduction of an expanded
line of Avenova® product bundles specifically designed to provide
easy, affordable and effective solutions for individualized relief
from dry eye symptoms. The new Avenova product bundles align with
findings among optometrists surveyed in the Eyes on Eyecare 2024
Dry Eye Report of the multifactorial nature of dry eye disease and
the recommendation that personalized treatment beyond artificial
tears may be important for successful management.
“Dry eye syndrome is one the most commonly observed clinical
diseases in the U.S. with approximately 16 million Americans suffer
from this condition. As dry eye and other ocular surface diseases
become increasingly prevalent, the U.S. dry eye syndrome treatment
market is projected to grow from $3.02 billion in 2023 to $4.86
billion by 2030 as more consumers seek relief,” said Justin Hall,
CEO of NovaBay. “Our new Avenova product bundles align with where
we see the market going, as confirmed by the 2024 Dry Eye Report.
The report specifically identified daily lid and lash hygiene as
among the top three approaches for patients for dry eye disease,
and hypochlorous acid as a top approach for patients with Demodex
blepharitis. The cornerstone of each product bundle is Avenova
Antimicrobial Lid & Lash Solution, the No. 1
physician-recommended hypochlorous acid lid and lash spray, which
is recommended for twice daily use. Importantly, Avenova spray is
formulated with our proprietary pure hypochlorous acid,
differentiating it from other hypochlorous acid sprays on the
market.
“Recognizing that dry eye can be stubborn with multiple
underlying causes, we broadened the Avenova product line over the
past several years to encompass a full portfolio of scientifically
developed products for each step of the standard dry eye treatment
regimen,” he added. “We are now taking the next step by offering
specially priced bundles that are essentially mini regimens with
fundamental modalities such as hygiene, heat therapy, hydration and
nutrition, to help consumers select a group of products to more
effectively combat their symptoms of dry eye. This bespoke approach
to improving consumer satisfaction is expected to further increase
Avenova brand loyalty.”
NovaBay offers everyday discounts on its Avenova product bundles
and is currently running a special additional 10% off introduction
on the already low price for new bundles. In addition to Avenova
spray, the Avenova over-the-counter product line includes the
Avenova Eye Health Support antioxidant-rich oral supplement,
Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye
Compress to soothe the eyes and the i-Chek by Avenova to monitor
physical eyelid health. Avenova product bundles are now available
on Avenova.com.
The 2024 Dry Eye Report surveyed 337 optometrists across the
U.S., with the majority as primary eye care and dry eye
specialists. According to respondents, more than 80% found dry eye
diagnosis and treatment moderately to extremely important in
generating revenue for their practices, and estimate that more than
two-thirds of their patients have some form of dry eye disease. Dry
eye was ranked as the second top area of specialization among those
surveyed, exceeded only by primary care, and is expected to account
for 43% of clinical focus in the next 12 months, up from 17% in
2023. Among the factors driving increased interest are the
escalating prevalence of dry eye, heightened awareness of
contributing factors and more diagnostic capabilities.
About NovaBay Pharmaceuticals, Inc. NovaBay’s leading
product Avenova® Antimicrobial Lid & Lash Solution is often
prescribed by eyecare professionals for blepharitis and dry eye
disease and is available directly to consumers through online
distribution channels such as Amazon.com. It is clinically proven
to kill a broad spectrum of bacteria to help relieve the symptoms
of bacterial dry eye, yet is non-irritating and completely safe for
regular use. In addition to this Avenova OTC product line, NovaBay
offers the Avenova Allograft, an amniotic tissue prescription-only
product, is available through eyecare professionals in the United
States.
Forward-Looking Statements This release contains
information about management's view of the Company's future
expectations, plans and prospects that constitute forward-looking
statements within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the fact that they
do not relate strictly to historic or current facts. Such
forward-looking statements are based upon management’s current
expectations, assumptions, estimates, projections and beliefs.
These statements include, but are not limited to, statements
regarding our business strategies, commercial progress, current and
potential future sales channels, and any future revenue, and the
timing of such revenue, that may result from these marketing
efforts, as well as generally the Company’s expected future
financial results. These statements involve risks, uncertainties
and other factors that may cause actual results or achievements to
be materially different and adverse from those expressed in or
implied by these forward-looking statements. Factors that might
cause or contribute to such differences include, but are not
limited to, risks and uncertainties relating to the size of the
potential market for our products, the Company’s products not being
able to penetrate one or more targeted markets and the Company’s
ability to continue as a going concern and revenues (or the
execution on capital raise opportunities) not being sufficient to
meet the Company’s cash needs. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-K/Q
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on X
Connect with NovaBay on LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513697418/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
NovaBay Pharmaceuticals (AMEX:NBY)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024